New Phase 3 olorofim data: fewer renal adverse events, but liver injury risk still warrants attention
Following the June announcement that the primary endpoint was met, the OASIS trial has disclosed longer-term mortality and organ safety results, clarifying the benefits and limitations of this new oral antifungal candidate.